

**ASX RELEASE****Market Update: Trajan set to report strong top line growth**

5 August 2025 –Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) announced today, as part of its financial results preparation, an update to the market on its performance for Financial Year 2025 (FY25).

Trajan's FY25 performance demonstrates continued progress toward our purpose of delivering science that benefits people, with record revenue reflecting strong market demand for our solutions. Based on initial unaudited FY25 year-end accounts, the Company confirms it expects to exceed the upper end of financial guidance for Net Revenue provided for FY25 (\$165.0M) with Net Revenue for the year at a record \$166.5M. This result demonstrates strong growth across the group of 7.4% compared to FY24, despite the loss of \$3.9M caused by the previously reported loss of a specialised biotech syringe revenue stream. This growth has outperformed much of the scientific instruments tooling sector globally and signals continued strong performance and contribution across Trajan's portfolio.

As flagged in the May 2025 market update, based on initial unaudited FY25 year-end accounts, Group nEBITDA is anticipated to fall short of the lower end of guidance (\$17.0M) by around 8.8% at approximately \$15.5M. This represents a 26.6% increase on FY24 (Group nEBITDA FY24 \$12.3M). Factors that have impacted the H2'25 result are:

- A negative impact of \$0.8M FX revaluation due to the movement in AUD/USD exchange rate which was not anticipated at half year;
- The expected shipping of microsampling orders (c \$1M) in June could not be completed prior to year end;
- A change in the geographical sales of the capital equipment market to the more price sensitive emerging markets in FY25 resulted in a lower-than-expected %GP; and
- The tariff announcements which caused the company to pivot operations towards more local fulfillment of orders, with supply chains having to be repositioned for the emerging market environment.

Initial indications of the FY25 Cash Position as of 30 June, which will be confirmed post audit, show that cash and equivalents increased to \$11.9M, reflecting continued strong organic cash generation. The Company's Net Debt is estimated to show a further reduction of \$3.3M during the year to \$29.6M. Importantly, net debt/nEBITDA leverage is expected to have improved from 2.7X to 1.9X at year end within the target range of less than 2.0X.

Long term debt arrangements, with terms more supportive of the company's growth aspirations, were changed to a new debt provider late in the FY, returning debt classification to non-current.



Trajan believes it is positioned well for continued EBITDA and margin expansion in FY26, with our diversified portfolio, strong customer relationships, and leadership in our key segments supporting our purpose to deliver science that benefits people. The Company will provide further insights at the Full Year Results, to be released on the 28<sup>th</sup> August.

**Authorised for ASX release by the Board of Trajan Group Holdings Limited.**

**END**

**Contact:**

**Investors**

Rebecca Wilson

Marie Krstic

[investorrelations@trajanscimed.com](mailto:investorrelations@trajanscimed.com)

**Media**

Ana Luiza Graça Harrop

Amy Miller

[media@trajanscimed.com](mailto:media@trajanscimed.com)

**About Trajan**

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.